Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Receivables (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Receivables for 16 consecutive years, with $12.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Receivables fell 5.63% to $12.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $12.1 million, a 5.63% decrease, with the full-year FY2024 number at $14.9 million, down 7.66% from a year prior.
  • Receivables was $12.1 million for Q3 2025 at Harvard Bioscience, up from $11.9 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $21.8 million in Q4 2021 to a low of $11.9 million in Q2 2025.
  • A 5-year average of $16.0 million and a median of $16.1 million in 2023 define the central range for Receivables.
  • Peak YoY movement for Receivables: skyrocketed 32.14% in 2021, then fell 26.13% in 2024.
  • Harvard Bioscience's Receivables stood at $21.8 million in 2021, then decreased by 23.49% to $16.7 million in 2022, then fell by 3.63% to $16.1 million in 2023, then dropped by 7.66% to $14.9 million in 2024, then decreased by 18.55% to $12.1 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Receivables are $12.1 million (Q3 2025), $11.9 million (Q2 2025), and $13.5 million (Q1 2025).